Core Viewpoint - Merit Medical Systems, Inc. (MMSI) has announced the acquisition of Biolife Delaware, L.L.C., which will enhance its hemostasis product portfolio and improve patient care [1][2][5]. Company Overview - The acquisition positions MMSI to provide more standardized and simplified post-procedure care solutions [1]. - Biolife's products, StatSeal and WoundSeal, are expected to address a $350 million global market opportunity [6]. Financial Guidance - MMSI has revised its full-year 2025 financial guidance to reflect the impact of the acquisition, projecting net revenues between $1.480 billion and $1.501 billion, an increase of 9.1-10.7% compared to 2024 [10]. - The Cardiovascular segment's net revenues are now expected to be between $1.407 billion and $1.426 billion, representing an increase of 8-10% over 2024 [11]. - Adjusted EPS for 2025 is projected to be in the range of $3.28-$3.41, reflecting a decrease of 5-1% compared to 2024 [12]. Market Performance - Following the acquisition announcement, MMSI's shares gained nearly 0.7% [3]. - The company has a market capitalization of $5.81 billion and a return on equity of 15.5%, outperforming the industry average of 14.3% [4]. Industry Prospects - The global hemostasis and tissue sealing agents market is projected to grow at a CAGR of 9% from 2025 to 2030, driven by increased surgery volumes and demand for critical care [13]. - The acquisition is expected to significantly boost MMSI's business in this growing market [14].

Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical +1-801-432-2864 +1-443-213-0509 Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare sarah.comstock@merit.com mike.piccinino@icrhealthcare.com FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE First Quarter Highlights† Exhibit 99.1 † Comparisons above are calculated for the current quarter compared with the first quarter of 2024, unless otherwise specified. Amounts stated in this release are ...

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to inclu ...

The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulatory approval fro ...

Core Insights - The article compares Labcorp (LH) and Merit Medical (MMSI) to determine which stock offers better value for investors [1] Valuation Metrics - Labcorp has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Merit Medical has a Zacks Rank of 4 (Sell) [3] - Labcorp's forward P/E ratio is 15.44, significantly lower than Merit Medical's forward P/E of 28.18 [5] - Labcorp has a PEG ratio of 1.57, while Merit Medical's PEG ratio is 2.74, suggesting Labcorp is expected to grow earnings at a more favorable rate [5] - Labcorp's P/B ratio is 2.50 compared to Merit Medical's P/B of 3.96, indicating Labcorp is more favorably valued against its book value [6] - Based on these metrics, Labcorp earns a Value grade of A, while Merit Medical receives a Value grade of D [6] Earnings Outlook - Labcorp is noted for its improving earnings outlook, which enhances its attractiveness as a value investment [7]

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium held in London, England, on April 23, 2025, during the Vascular Access Mas ...

Merit Medical Systems, Inc. (MMSI) reported first-quarter 2025 adjusted earnings per share (EPS) of 86 cents, up 14.7% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 14.7%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)GAAP EPS for the quarter was 49 cents, down by a penny year over year.MMSI’s Revenue DetailsRevenues grossed $355.4 million in the reported quarter, up 9.8% year over year on a reported basis. The metric topped the Zacks Consens ...

Merit Medical Systems (MMSI) Q1 2025 Earnings Call April 25, 2025 02:35 AM ET Company Participants Fred Lampropoulos - Founder, CEO & ChairmanBrian Lloyd - Chief Legal Officer and Corporate SecretaryRaul Parra - CFO & TreasurerSimran Modi - Vice PresidentMichael Petusky - Managing DirectorJon Young - DirectorJayson Bedford - Managing Director, Equity Research Conference Call Participants Jason Bednar - Senior Research AnalystSteve Lichtman - Managing Director, Senior Research AnalystRobbie Marcus - AnalystC ...

Financial Data and Key Metrics Changes - The company reported total revenue of $355.4 million, up 9.8% year-over-year on a GAAP basis and up 10.9% year-over-year on a constant currency basis, exceeding growth expectations [11][12] - Non-GAAP operating margin increased nearly 230 basis points year-over-year to 19.3%, representing a first quarter record for the company [12][29] - Non-GAAP EPS grew by 15%, exceeding the high end of expectations [12][30] Business Line Data and Key Metrics Changes - Cardiovascular segment sales grew by 9%, while Endoscopy segment sales surged by 64% [17][18] - Cardiac intervention product sales increased by 12%, driven primarily by the acquisition of Cook Medical Products [20] - Sales of OEM products increased by 21%, significantly outperforming guidance [21] Market Data and Key Metrics Changes - U.S. sales increased by 14% on a constant currency basis, exceeding expectations [23] - International sales grew by 6% year-over-year, with APAC and EMEA regions performing at the high end of expectations [24] - Sales in China decreased by 10%, attributed to broader macroeconomic conditions rather than specific demand issues [25][62] Company Strategy and Development Direction - The company remains focused on delivering strong execution, solid constant currency growth, and free cash flow generation in 2025 [15][37] - Updated financial guidance reflects the impact of tariffs and trade policies, with non-GAAP EPS expectations adjusted to $3.29 to $3.42 [34][37] - The company is implementing cost control measures and leveraging existing initiatives to mitigate tariff impacts [40][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate challenges posed by tariffs and macroeconomic conditions [41][112] - The company is monitoring the tariff situation closely but is not making long-term decisions based on short-term fluctuations [110][112] - Management remains optimistic about the demand for products in China despite recent challenges [63][99] Other Important Information - The company generated $19.5 million of free cash flow in Q1 2025, down 20% year-over-year due to increased capital expenditures [32] - Total debt obligations stood at $747.5 million, with a net leverage ratio of 1.8x as of March 31, 2025 [33] Q&A Session Summary Question: Can you provide more color on mitigation efforts regarding tariffs? - Management indicated that mitigation efforts are centered around existing initiatives and operational efficiencies, with a focus on maintaining execution [54][56] Question: What is the outlook for demand in China? - Management noted that the softer revenue results in China were primarily due to macroeconomic factors, and they have not changed their full-year outlook for the region [62][99] Question: How is the company managing tariff impacts on free cash flow? - Management emphasized that they have a plan in place to manage working capital and mitigate tariff impacts, maintaining a free cash flow guidance of at least $150 million for 2025 [90][94] Question: What is driving the recent growth in the OEM business? - Management attributed the growth to new accounts and the company's longstanding reputation for quality and reliability, rather than inventory pull-forward due to tariffs [101][105]

For the quarter ended March 2025, Merit Medical (MMSI) reported revenue of $355.35 million, up 9.8% over the same period last year. EPS came in at $0.86, compared to $0.77 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $352.33 million, representing a surprise of +0.86%. The company delivered an EPS surprise of +14.67%, with the consensus EPS estimate being $0.75.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...